A new experimental drug called J27 significantly reduced heart damage and improved heart function in obese mice by blocking a protein called JNK2, according to research reviewed by Gram Research. The drug fixed calcium imbalance in heart cells and reduced harmful inflammation from immune cells. While these results are promising, J27 has only been tested in mice and laboratory cells, not humans, so it would take many more years of research before it could potentially be used as a treatment for people with obesity-related heart disease.

Scientists have discovered that a new experimental drug called J27 may help protect the heart from damage caused by obesity. According to Gram Research analysis, the compound works by blocking a specific protein called JNK2 that plays a key role in heart injury. In studies using mice fed a high-fat diet, J27 reduced heart enlargement, improved heart function, and decreased inflammation. While this research is still in early stages and hasn’t been tested in humans yet, it represents an important step toward developing the first treatment specifically designed to fix obesity-related heart damage rather than just treating the symptoms.

Key Statistics

An experimental drug called J27 markedly reduced heart enlargement and improved cardiac function in a dose-dependent manner in mice fed a high-fat diet, according to a 2026 study published in International Immunopharmacology.

Genetic removal of the JNK2 protein completely eliminated J27’s protective effects on the heart, proving that JNK2 is the specific molecular target responsible for the drug’s therapeutic actions in obesity-induced heart disease.

J27 restored normal calcium handling in heart cells by inhibiting the JNK2/CaMKIIδ signaling pathway and suppressed inflammatory immune responses through the JNK2/c-Jun pathway, addressing two major mechanisms of obesity-related heart damage simultaneously.

The Quick Take

  • What they studied: Whether a new drug called J27 could protect mouse hearts from damage caused by eating a high-fat diet, and how it works at the cellular level.
  • Who participated: Laboratory mice fed a high-fat diet to mimic obesity-related heart disease, plus heart cells and immune cells grown in dishes and treated with fatty acids.
  • Key finding: J27 significantly reduced heart enlargement and improved heart function in obese mice in a dose-dependent way, meaning higher doses worked better. The drug also reduced inflammation and fixed problems with how heart cells handle calcium.
  • What it means for you: This is early-stage research that shows promise for a completely new type of heart medicine for people with obesity-related heart problems. However, it has only been tested in mice so far, and human trials would be needed before anyone could use it. People with obesity-related heart disease should continue following their doctor’s current treatment plans.

The Research Details

Researchers created a mouse model of obesity-related heart disease by feeding mice a high-fat diet. They then gave some mice the experimental drug J27 and compared their hearts to mice that didn’t receive the drug. The scientists examined the hearts using multiple methods including looking at tissue samples under a microscope, measuring chemical markers in the blood, and using ultrasound to watch the heart beating.

At the same time, the researchers grew heart cells and immune cells in laboratory dishes and exposed them to palmitic acid, a type of fat that damages heart tissue. They tested whether J27 could protect these cells from injury and reduce inflammation.

To prove that J27 worked by blocking JNK2 specifically, the scientists also used genetic techniques to remove the JNK2 protein entirely from some mice. If J27 stopped working when JNK2 was removed, that would prove JNK2 was the target.

This research approach is important because it combines animal studies with laboratory cell studies to understand both how a drug works and whether it actually helps. Testing in mice first allows scientists to see if a drug is safe and effective before considering human trials. The genetic experiments that removed JNK2 were especially important because they proved that J27 works specifically by blocking this one protein, not by accident.

This study was published in a peer-reviewed scientific journal, meaning other experts reviewed it before publication. The research used multiple methods to measure heart health, which makes the findings more reliable. However, this is still early-stage research in animals only. The study did not specify the exact number of mice used, which makes it harder to judge how solid the results are. Animal studies don’t always translate to humans, so much more research would be needed before this drug could be tested in people.

What the Results Show

In mice fed a high-fat diet, J27 treatment significantly reduced heart enlargement and improved how well the heart pumped blood. The drug worked in a dose-dependent manner, meaning that higher doses produced better results. The mice that received J27 showed less scarring in the heart tissue compared to untreated mice.

At the cellular level, J27 fixed a major problem in obese hearts: calcium imbalance. Heart cells need calcium to contract properly, but in obesity-related heart disease, calcium handling goes wrong. J27 restored normal calcium handling by blocking a specific signaling pathway called JNK2/CaMKIIδ.

The drug also reduced inflammation in the heart. Immune cells called macrophages become overactive in obese hearts and damage heart cells. J27 calmed down these immune cells by blocking the JNK2/c-Jun pathway, which reduced the harmful signals they sent to heart cells.

When researchers genetically removed the JNK2 protein from mice, J27 no longer worked. This proved that JNK2 is the specific target that makes J27 effective.

The research showed that JNK2 acts as a master control switch in obesity-related heart disease. By blocking this one protein, J27 fixed multiple problems at once: calcium handling in heart cells, inflammation from immune cells, and the crosstalk between immune cells and heart cells. This suggests that targeting JNK2 might be more effective than trying to fix each problem separately.

Current treatments for obesity-related heart disease focus on indirect approaches like weight loss, exercise, and cholesterol-lowering drugs. These treatments help but don’t directly fix the damaged heart tissue. This research is novel because J27 is the first drug designed to specifically target the molecular mechanisms that cause obesity-related heart damage. Previous research identified JNK2 as important in heart disease, but this study is the first to show that blocking it with a selective drug can protect the heart in obesity.

This research was conducted entirely in mice and laboratory cells, not humans. Mouse hearts may respond differently to the drug than human hearts would. The study did not report the exact number of mice used or provide detailed statistical analysis, making it harder to judge how reliable the findings are. The long-term safety of J27 was not tested. The drug has never been given to humans, so we don’t know if it would be safe or effective in people. Additional research in larger animal models and eventually human clinical trials would be necessary before this drug could be used as a treatment.

The Bottom Line

This research provides strong evidence that blocking JNK2 could be a promising new approach to treating obesity-related heart disease. However, these findings are from animal studies only. Current recommendations for people with obesity-related heart problems remain weight loss, regular exercise, heart-healthy eating, and medications prescribed by their doctor. People should not expect this drug to be available soon, as it would need to go through many more years of testing before it could be used in humans. Confidence level: Moderate for the scientific concept, but low for immediate clinical application.

This research is most relevant to people with obesity who have heart problems, cardiologists who treat heart disease, and pharmaceutical companies developing new heart medications. People with obesity-related heart disease should be aware that new treatments are being developed, but they should continue following their current treatment plans. This research is not yet relevant to the general public or people without obesity-related heart disease.

If J27 moves forward in development, it would typically take 5 to 10 years of additional testing before it could potentially be available as a prescription medication. This includes safety testing in larger animals, human clinical trials in phases 1, 2, and 3, and regulatory approval. Even if development goes smoothly, this drug would not be available to patients for many years.

Frequently Asked Questions

Can I take J27 if I have heart problems from obesity?

J27 is not yet available for human use. It has only been tested in mice and laboratory cells. If approved after human trials, it could take 5 to 10 years to become available. Continue following your doctor’s current treatment plan for now.

How does J27 protect the heart in obesity?

J27 blocks a protein called JNK2 that causes two main problems in obese hearts: calcium imbalance in heart cells and excessive inflammation from immune cells. By blocking JNK2, the drug fixes both problems at once.

This research shows J27 could complement weight loss, not replace it. Weight loss remains the most important treatment. J27 might help protect the heart while people work on losing weight, but this hasn’t been tested in humans yet.

When will J27 be available as a treatment?

If development continues successfully, J27 would need 5 to 10 years of additional testing including human clinical trials before it could potentially be approved and prescribed by doctors. There is no guarantee it will ever reach patients.

Work with your cardiologist on proven treatments: weight loss, regular exercise, heart-healthy eating, and prescribed medications. Stay informed about new research, but don’t delay current treatment while waiting for experimental drugs to be developed.

Want to Apply This Research?

  • Users with obesity-related heart disease could track their heart health markers that their doctor monitors: resting heart rate, blood pressure readings, and any symptoms like shortness of breath or chest discomfort. Recording these weekly in an app would help them see if their current treatments are working and provide data to share with their doctor.
  • Users could set goals for weight loss, daily steps, and heart-healthy meals. The app could send reminders to take prescribed heart medications on time and log exercise sessions. Users could also track how they feel during physical activity to notice improvements in heart function over time.
  • Create a long-term dashboard showing trends in weight, exercise, blood pressure, and heart rate over months and years. Users could share monthly summaries with their cardiologist to track progress. The app could alert users if readings become concerning and suggest contacting their doctor. This ongoing monitoring would help users and doctors assess whether current treatments are working while new options like J27 are being developed.

This article describes early-stage research conducted in mice and laboratory cells. J27 has not been tested in humans and is not approved for any medical use. This information is for educational purposes only and should not be considered medical advice. People with obesity-related heart disease should continue following their doctor’s current treatment recommendations and consult with their cardiologist before making any changes to their care plan. Do not delay or avoid proven treatments while waiting for experimental drugs to be developed. Always discuss new research findings with your healthcare provider to determine what is appropriate for your individual situation.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Compound J27 alleviates obesity-induced cardiomyopathy by targeting JNK2. , International immunopharmacology (2026). PubMed 42594841 | DOI
Topics
obesity-induced cardiomyopathy heart disease obesity JNK2 inhibitor experimental heart drug cardiac dysfunction treatment inflammation heart disease obesity heart damage new heart medication